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Long-Term Prognostic Risk in Lower Extremity Peripheral Arterial
Disease as a Function of the Number of Peripheral Arterial Lesions
Kim G. Smolderen, PhD; Moniek van Zitteren, MD, MSc, PhD; Philip G. Jones, MS; John A. Spertus, MD, MPH; Jan M. Heyligers, MD, PhD;
Maria J. Nooren, MA; Patrick W. Vriens, MD, PhD; Johan Denollet, PhD
Background-—Although patients with peripheral artery disease (PAD) are known to have an increased risk of adverse prognosis,
simple techniques to further risk-stratify PAD patients would be clinically useful. A plausible but unexplored factor to predict such
risk would be greater disease burden, manifested as multiple lower extremity lesions. The aim of this study was to examine the
association between having multiple versus isolated lower extremity PAD lesions and long-term prognosis.
Methods and Results-—A prospective cohort of 756 newly diagnosed PAD patients underwent duplex ultrasound testing to
determine the number of lower extremity lesions. Cox regression models examined the independent association of lesion number
(≥3 and 2 versus 1) and adverse prognosis (defined as a composite end point comprising first occurrence of either lower extremity
amputation, admission for heart failure, nonfatal stroke, myocardial infarction, or unstable angina or mortality), adjusting for
demographic and clinical risk factors. Analyses were replicated using an advanced Cox-based model for multiple events. A total of
173 patients (23%) had ≥3 lesions, 197 (26%) had 2 lesions, and 386 (51%) had 1 lesion. After a median follow-up of 3.2 years,
patients with ≥3 lesions had an increased risk of experiencing a first adverse event (adjusted hazard ratio 1.60, 95% CI 1.08–2.38,
P=0.020) and an increased risk of having multiple events (adjusted hazard ratio 1.53, 95% CI 1.08–2.18, P=0.018). Patients with 2
lesions had a prognosis similar to those with 1 lesion.
Conclusions-—Among PAD patients, a greater number of lesions is associated with an increased risk of an adverse prognosis over
3 years of follow-up. Assessing the number of lower extremity lesions might serve as a simple risk-stratification tool at initial PAD
diagnosis. ( J Am Heart Assoc. 2015;4:e001823 doi: 10.1161/JAHA.115.001823)
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P atients with peripheral arterial disease (PAD) are avulnerable population because they not only experience functional impairment
1,2 but also face an excess risk of an
adverse prognosis (eg, myocardial infarction [MI], angina,
stroke, heart failure, lower extremity amputation, and death)
due to concomitant coronary and cerebrovascular disease.3–5
This risk of an adverse prognosis is applicable to the whole
spectrum of PAD patients and thus mandates aggressive
cardiovascular risk factor control through the prescription of
statins, antiplatelet therapy, and smoking cessation.6–8 There
have been few efforts, however, to further risk-stratify
patients with PAD at the time of their initial presentation. A
simple marker of a worse prognosis could be the extent of
disease, as suggested by the number of obstructive lesions
identified at presentation. The clinical logic is that a greater
number of lesions may reflect a more aggressive disease
process, not only in the peripheral arteries but also in the
coronary and cerebral vasculature. Risk-stratifying PAD
patients may be clinically useful so that more intensive
follow-up and more aggressive treatment might be consid-
ered, including a more thorough workup and screening for
occult coronary or cerebrovascular disease.
It is expected that patients presenting with multiple lower
extremity arterial lesions are more likely to be at increased
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risk of having any or multiple adverse events than those
having a single lesion; however, this assumption has not been
thoroughly quantified in PAD patients.9 Initial evidence to
support our hypothesis is provided by secondary analyses of
the BASIL trial, in which the number of detectable ankle
pressures in critical limb ischemia patients—a more advanced
presentation of PAD—was positively associated with better
2-year survival outcomes.10 To further address this gap in
knowledge in patients with earlier stages of PAD, our objectives
were to document patient risk of experiencing a first adverse
event and multiple adverse events (defined as a composite end
point of either lower extremity amputation, admission for heart
failure, nonfatal stroke, MI, or unstable angina or mortality)
after an initial PAD diagnosis (Rutherford grade I, including
patients with mild, moderate, and severe claudication) as a
function of the number of lower extremity arterial lesions
identified. We also explored whether the risk associated with
number of lesions differed by the type of adverse event (lower
extremity amputation, unstable angina, MI, heart failure,
stroke, or death). This information could support better
quantification of PAD patient risk for subsequent events and
may provide clinicians with an easy way to risk-stratify patients
with new onset or worsening symptoms of PAD.
Methods
Patients and Study Design
A total of 756 PAD patients were systematically followed for a
median of 3.2 years (1.6 years, interquartile range 1.7 to
4.5 years; verification of adverse prognosis information
occurred up to January 1, 2012). Patients were consecutively
enrolled from 2 vascular surgery outpatient clinics (St.
Elisabeth Hospital and TweeSteden Hospital, Tilburg, Nether-
lands) between March 2006 and October 2011 if they
presented with new-onset PAD symptoms or exacerbation of
existing PAD requiring re-evaluation and treatment. Other
inclusion criteria were abnormal resting ankle-brachial index
(ABI; ≤0.90) or a decrease in postexercise ABI ≥15% following
a distance-limited treadmill test. Patients with critical limb
ischemia were excluded because their clinical trajectories,
treatments, and outcomes look vastly different from those of
patients with PAD who present with earlier stages of the
disease. Patients were also excluded if they had a noncom-
pressible ABI (≥1.30), severe cognitive impairment, or severe
psychiatric or somatic comorbidities (eg, psychosis or active
cancer treatment) or if they did not have sufficient knowledge
of the Dutch language. Because the focus of this study was on
the number of lower extremity lesions, patients were excluded
if no preprocedural duplex ultrasound examination was
available from their medical records within 3 months of
enrollment (Figure S1 provides an overview of exclusions).
All patients underwent noninvasive vascular laboratory
testing as part of their clinical evaluation for PAD including
resting and postexercise ABI measurements and a duplex
ultrasound examination. Information on demographic and
socioeconomic factors was obtained from patients at baseline
through purpose-designed questionnaires, and information on
clinical factors was collected through medical chart abstrac-
tion. Finally, up-to-date vital status information until January 1,
2012, was retrieved from patients’ electronic medical records,
which contained information on in-hospital deaths and deaths
that occurred outside the hospital because records are linked
to the regional social security death index of the Tilburg
community. Information on deaths occurring outside the
Tilburg community was provided by patients’ general practi-
tioners.
The study was designed in accordance with the Helsinki
Declaration and approved by the local institutional review




The primary outcome of this study was a combination of any
of the following events, as documented by patients’ hospital
or death records: (1) PAD-related major lower extremity
amputation, (2) heart failure, (3) nonfatal stroke, (4) nonfatal
MI or unstable angina, (5) fatal MI or stroke, (6) other
cardiovascular deaths (cardiac arrest, heart failure, sepsis),
and (7) other causes of death (exacerbation of chronic
obstructive pulmonary disease, cancer). Data on adverse
events were abstracted from patients’ medical records based
on the diagnosis and treatment discharge codes and
discharge notes and adjudicated by a team of 3 physicians
(surgical fellow and 2 vascular surgeons).
Vascular laboratory assessments
Patient ABI was read from a handheld Doppler instrument
(Imexlab 9000; Imex Medical Systems Inc) used by trained
vascular technicians. Both resting and postexercise ABIs
were obtained in both legs. The lowest resting ABI value
was used in our analyses. The exercise protocol included a
distance-limited treadmill test (1000 m) from which the
pain-free walking and maximum walking distances were
derived.
Duplex ultrasound examination protocol
Information on number of lesions, anatomical lesion location,
and lesion severity, as indicated by the peak systolic velocity
(PSV) ratio (in cm/s), was derived from duplex ultrasound
examinations prior to the initiation of any treatment. A
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detailed description of the duplex ultrasound examination
protocol was published previously.11
A team of 3 physicians (surgical fellow and 2 vascular
surgeons) adjudicated the duplex information; they quantified
and classified patients based on the number of peripheral
arterial lesions. Lesions with a PSV ratio ≥2.5 or total
occlusions were considered significant, and lesions with a
PSV ratio >0 to <2.5 were considered nonsignificant.6,11–13
The numbers of nonsignificant and significant lesions were
documented from duplex ultrasound readings. The number of
significant lower extremity lesions at the patient level was
used in our analyses. When determining the number of
lesions, each significant lesion was counted as 1 lesion,
regardless of its anatomical location in the peripheral
arteries. If a patient had, for example, multiple lesions in
the superficial femoral artery, then all significant lesions were
counted.
The peripheral vascular lesions were categorized into 3
categories: (1) proximal lesions (aortoiliac segments including
the distal abdominal aorta, right and left common iliac artery,
right and left external iliac artery, and bifurcation of the right
and left internal iliac artery); (2) distal lesions (femoropopliteal
segments including the right and left common femoral artery,
bifurcation of the right and left deep femoral artery, the right
and left superficial femoral artery, and right and left popliteal
artery and crural segments including the right and left
posterior tibial artery, right and left peroneal artery, and right
and left anterior tibial artery); and (3) both proximal and distal
lesions, which included lesions or occlusions that presented
at both proximal and distal locations. Because these 3
categories were not mutually exclusive, each lesion location
category was compared against all patients who were not in
that category. In our multivariable analyses, having any
proximal lesions was compared against having distal lesions
only. Duplex ultrasonography has a median sensitivity of 88%
(95% CI 80% to 98%) and a specificity of 96% (95% CI 89% to
99%) to detect a stenosis of ≥50% or an occlusion when
imaging the whole leg versus the standard of contrast
angiography.14
Patient characteristics
Information on clinical factors was abstracted from patients’
medical records and included cardiovascular history (prior
angina, MI, coronary artery bypass grafting, percutaneous
coronary intervention, heart failure, stroke, and transient
ischemic attack), other clinical risk factors (current smoking
status, diabetes mellitus, hypertension, dyslipidemia, chronic
obstructive pulmonary disease, body mass index [in kg/m2],
renal dysfunction, total cholesterol levels [in mg/dL], high-
density lipoprotein cholesterol [in mg/dL], systolic brachial
blood pressure [ie, the highest of 2 arms in mm Hg], back
pain, and hip or knee osteoarthritis), and medications that
patients were on following their vascular workup.
Demographic factors were obtained from patients’ med-
ical records and included age and sex. Socioeconomic
factors were derived from purpose-designed questionnaires
and included patients’ marital status (no partner versus
partner), education (less than a high school degree versus
high school degree or higher), and work status (nonactive
versus active).
Statistical Analysis
The analyses conducted for this study were patient based,
meaning that the counts of lesions were cumulative across
lower extremities within a patient. Patients were categorized
by the number of significant lower extremity lesions, as
derived from the duplex ultrasound readings, as ≥3 lesions
(≥3 lesions with a PSV ratio ≥2.5 and/or total occlusions), 2
lesions (2 lesions with a PSV ratio ≥2.5 and/or total
occlusions), or 1 lesion (1 lesion with a PSV ratio ≥2.5 or 1
occlusion, or nonsignificant lesions with a PSV ratio >0 to
<2.5).
Baseline patient characteristics were described for the
total population and compared among the 3 groups.
Categorical variables were analyzed by the chi-square test,
and 1-way ANOVA was used to analyze continuous
variables.
Due to power considerations, the association between the
number of lesions (≥3 or 2 versus 1) and adverse events was
analyzed using a composite end point (ie, amputation,
unstable angina, MI, heart failure, stroke, and death). In
addition, a multivariate analysis examined the association
between the number of lesions and adverse event type.
Time-to-first-event analysis
Patients were followed for a median of 3.2 years (1.6 years,
interquartile range 1.7–4.5 years). The incidence of adverse
events by ≥3 or 2 versus 1 lesion (reference) was plotted by
Kaplan–Meier curves, and survival curves were tested by the
log-rank test. Risk estimates (hazard ratios [HRs] and their
95% CIs) for the association between having ≥3 or 2 versus 1
(reference) lower extremity lesion and experiencing a first
major adverse event at 3.2-year follow-up were calculated
using a traditional time-to-first-event Cox regression model.
Multivariable analyses were adjusted for the following a priori
selected covariates: demographics (age, sex), resting ABI,
cardiovascular history (angina, MI, percutaneous coronary
intervention, coronary artery bypass grafting, heart failure,
stroke, transient ischemic attack), other clinical risk factors
(body mass index, chronic obstructive pulmonary disease,
hypertension, hyperlipidemia, diabetes, renal dysfunction,
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smoking status, total cholesterol, high-density lipoprotein
cholesterol, systolic blood pressure), and presence of
proximal versus nonproximal lesions (reference). Baseline
hazards were also stratified by hospital. Effects of continuous
variables (age, body mass index, ABI) were tested for linearity
using restricted cubic splines. Proportional hazards assump-
tions were evaluated using Schoenfeld residuals.
Sensitivity analysis
A sensitivity analysis was performed to evaluate the associ-
ation between having ≥3 or 2 versus 1 lesion (reference) and
3.2-year risk of multiple adverse events, as opposed to the
main time-to-first-event analysis, using an unadjusted and
adjusted Cox-based intensity-elapsed time model15 including
the same covariates as in the time-to-first-event analysis. This
model assumes that all events are equally likely to occur,
independent of prior events, with the risk of each event
starting from “time zero,” the time of initial enrollment.15 The
within-patient correlation was modeled by a frailty term (ie, a
random component to account for within-patient correlation).
The mean cumulative incidence of events was also calculated,
stratified by the number of lesions (≥3 or 2 versus 1 lesion
[reference]).
Event-specific analyses
Given the composite nature of the outcome, a multivariate
Cox regression model was constructed to evaluate whether
the risk associated with number of lesions varied by event
type. This analysis modeled time to first event separately for
each type of event, with event-specific baseline hazard
functions, an interaction between number of lesions and
event type, adjustment for other covariates as described
above, and a frailty term to model within-patient correlation. A
secondary analysis was performed to evaluate the association
between the number of arterial lesions and cumulative
incidence of major adverse cardiac events, including fatal or
nonfatal MI or stroke. Deaths due to other causes were
treated as competing risk events. Because only 12 patients
experienced multiple events of the same type, this analysis
modeled only time to first event.
The follow-up data for adverse events were complete.
Covariate data were complete except for body mass index,
total cholesterol, high-density lipoprotein cholesterol, and
systolic blood pressure, which were missing on 16%, 12%,
12%, and 4% of patients, respectively. For modeling purposes,
missing values were imputed using single regression imputa-
tion on all other available covariates and outcomes.
All statistical analyses were performed with SAS software
version 9.3 (SAS Institute Inc) and R software version 2.14.1
(R Foundation). All tests were 2-tailed, and P values <0.05
were considered statistically significant.
Results
Baseline Characteristics by Number of Lesions
Of the 756 included patients, 173 (23%) presented with ≥3
lesions, 197 (26%) had 2 significant lesions, and 386 (51%) had
a nonsignificant lesion (n=77) or 1 significant lesion (n=309).
Table 1 summarizes patient characteristics for the total
study population stratified by the number of lower extremity
arterial lesions. The mean age of the population was 65 years
(10 years, range 37–92 years), and 65% were male. Patients
with ≥3 lesions were older; lower rates of having a partner were
noted, whereas higher rates of prior cardiovascular history and
use of cardiovascular medications, antidepressants, and hyp-
notics were observed. Patients with ≥3 lesions presented with
higher proportions of distal lesions and lesions in both proximal
and distal segments. Finally, patient maximum walking dis-
tance, resting ABI, and postexercise ABI values were also lower
in patients with ≥3 lesions as compared with patients having
fewer lesions.
Adverse Events
A total of 218 adverse events occurred among 155 patients
(20%) who experienced at least 1 event and among 41
patients (5%) who had at least 2 events during follow-up.
Table 2 summarizes the crude cumulative incidence rates
stratified by event type; deaths (n=87) were the most
commonly documented events.
Time-to-First-Event Analysis
Figure 1 presents the cumulative incidence over time for
experiencing a first adverse event, illustrating that the
cumulative incidence was higher for patients presenting with
≥3 lesions (log-rank test P<0.0001). Results from the time-to-
first-event Cox regression analysis indicated that patients
presenting with ≥3 lesions were more likely to experience a
first adverse event during 3.2-year follow-up compared with
those presenting with 1 lesion in the unadjusted model
(unadjusted HR 2.05, 95% CI 1.43–2.93, P≤0.0001). No
increased risk of experiencing a first adverse event was
observed among patients presenting with 2 versus 1 lesion
(unadjusted HR 0.93, 95% CI 0.62–1.42, P=0.75).
Results from the multivariable time-to-first-event analysis
are listed in Table 3. The presence of ≥3 lesions (HR 1.60,
95% CI 1.08–2.38, P=0.020) remained an independent
predictor of experiencing an adverse event. Other significant
covariates included age (HR per +10 years 1.32, 95% CI 1.08–
1.62, P=0.006) and chronic obstructive pulmonary disease
(HR 2.11, 95% CI 1.46–3.06, P≤0.001). The c-index for the
multivariable model was 0.69.
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Age (meanSD), y 65.09.8 68.010.2 64.99.6 63.89.5 <0.001
Age <50 years, n (%) 50 (6.6) 6 (3.5) 14 (7.1) 30 (7.8) 0.002
Age 50 to 69 years, n (%) 430 (56.9) 82 (47.4) 114 (57.9) 234 (60.6)
Age ≥70 years, n (%) 276 (36.5) 85 (49.1) 69 (35.0) 122 (31.6)
Male sex, n (%) 489 (64.7) 117 (67.6) 136 (69.0) 236 (61.1) 0.11
Socioeconomic factors
No partner, n (%) 162 (21.4) 51 (34.9) 40 (23.7) 71 (21.5) 0.007
Less than high school degree,
n (%)
165 (21.8) 42 (29.2) 45 (26.6) 78 (23.8) 0.45
Active working status, n (%) 163 (21.6) 25 (18.2) 48 (28.7) 90 (28.1) 0.06
Cardiovascular risk factors
Prior angina, n (%) 112 (14.8) 39 (22.5) 19 (9.6) 54 (14.0) 0.002
Prior myocardial infarction, n (%) 140 (18.5) 48 (27.7) 35 (17.8) 57 (14.8) 0.001
Prior coronary artery bypass
grafting, n (%)
82 (10.8) 26 (15.0) 17 (8.6) 39 (10.1) 0.11
Prior percutaneous coronary
intervention, n (%)
70 (9.3) 15 (8.7) 21 (10.7) 34 (8.8) 0.73
Heart failure, n (%) 36 (4.8) 9 (5.2) 8 (4.1) 19 (4.9) 0.86
Prior transient ischemic attack,
n (%)
66 (8.7) 24 (13.9) 13 (6.6) 29 (7.5) 0.023
Prior stroke, n (%) 59 (7.8) 16 (9.2) 16 (8.1) 27 (7.0) 0.64
Clinical factors
Body mass index, meanSD 26.84.9 26.44.6 26.53.9 27.15.5 0.25
Total cholesterol, mg/dL
(meanSD)
193.346.0 186.845.1 194.045.4 195.946.5 0.13
High-density lipoprotein
cholesterol, mg/dL (meanSD)
49.214.3 48.813.0 51.017.4 48.512.9 0.15
Systolic blood pressure, mm Hg
(meanSD)
158.722.6 161.6 25.4 159.221.1 157.221.8 0.10
Smoking, n (%) 375 (49.6) 75 (43.4) 99 (50.3) 201 (52.1) 0.16
Diabetes mellitus, n (%) 183 (24.2) 43 (24.9) 47 (23.9) 93 (24.1) 0.97
Hyperlipidemia, n (%) 512 (67.7) 126 (72.8) 127 (64.5) 259 (67.1) 0.21
Hypertension, n (%) 452 (59.8) 113 (65.3) 115 (58.4) 224 (58.0) 0.24
Chronic obstructive pulmonary
disease, n (%)
136 (18.0) 29 (16.8) 36 (18.3) 71 (18.4) 0.89
Renal dysfunction, n (%) 69 (9.1) 22 (12.7) 18 (9.1) 29 (7.5) 0.14
Back pain, n (%) 113 (14.9) 19 (11.0) 34 (17.3) 60 (15.5) 0.22
Hip or knee osteoarthritis, n (%) 156 (20.6) 33 (19.1) 43 (21.8) 80 (20.7) 0.81
Medication use
Aspirin, n (%) 586 (77.5) 137 (79.2) 149 (75.6) 300 (77.7) 0.71
Statins, n (%) 616 (81.5) 145 (83.8) 164 (83.2) 307 (79.5) 0.37
Beta blocker, n (%) 315 (41.7) 79 (45.7) 72 (36.5) 164 (42.5) 0.19
Continued
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Sensitivity Analyses
A total of 41 patients (5%) experienced >1 adverse event over
time. Sensitivity analyses were performed to calculate the
cumulative 3.2-year risk of experiencing multiple adverse
events by the number of lesions (≥3 or 2 versus 1 lesion
[reference]) using an unadjusted and multivariable adjusted
Cox-based intensity-elapsed time model. The mean cumulative
incidence of multiple adverse events by the number of lesions
was significantly higher for patients with ≥3 lesions (log-rank
test P=0.0001) (Figure S2). Apart from the risk of experiencing a
first adverse event, having ≥3 lesions (HR 1.68, 95% CI 1.20–
2.36, P=0.003) was also associated with an increased cumu-
lative risk of experiencing >1 adverse event during 3.2 years of
follow-up. Other relevant indicators of an increased cumulative
risk were age, prior MI, chronic obstructive pulmonary disease,
heart failure, and smoking (Table S1 shows full model results).
Event-Specific Analyses
Results from the multivariate Cox regression analysis of time
to first event, stratified by event type, demonstrated that
prior MI (HR 2.65, 95% CI 1.26–5.55, P=0.018) and death
(HR 2.50, 95% CI 1.53–4.08, P=0.002) were the events more
likely to occur in patients presenting with ≥3 lesions
compared with those having 1 lesion (Figures 2 and 3);
however, because of the low number of individual event
types, the interaction between number of lesions and event
type was not significant (P=0.62). Results from the sec-
ondary analysis that evaluated the association between the
number of arterial lesions and major adverse cardiac events
indicated that patients having a higher number of arterial
lesions had higher cumulative incidence of major adverse











Diuretics, n (%) 190 (25.1) 57 (32.9) 50 (25.4) 83 (21.5) 0.016
Angiotensin-converting enzyme
inhibitor, n (%)
234 (31.0) 68 (39.3) 62 (31.5) 104 (26.9) 0.014
Calcium antagonist, n (%) 167 (22.1) 45 (26.0) 47 (23.9) 75 (19.4) 0.18
Nitroglycerin, n (%) 67 (8.9) 25 (14.5) 16 (8.1) 26 (6.7) 0.011
Anticoagulants, n (%) 125 (16.5) 40 (23.1) 30 (15.2) 55 (14.2) 0.028
Digoxin, n (%) 18 (2.4) 9 (5.2) 3 (1.5) 6 (1.6) 0.042
Antiarrhythmics, n (%) 21 (2.8) 8 (4.6) 4 (2.0) 9 (2.3) 0.27
Antidepressives, n (%) 45 (6.0) 13 (7.5) 3 (1.5) 29 (7.5) 0.009
Anxiolytics, n (%) 31 (4.1) 9 (5.2) 4 (2.0) 18 (4.7) 0.22
Hypnotics, n (%) 34 (4.5) 16 (9.2) 3 (1.5) 15 (3.9) 0.001
Anatomical lesion location <0.001
Nonsignificant lesion, n (%) 71 (9.4) 0 (0.0) 0 (0.0) 71 (19.2)
Proximal lesions, n (%) 219 (29.0) 31 (19.3) 69 (36.7) 119 (32.2)
Distal lesions, n (%) 363 (48.0) 89 (55.3) 94 (50.0) 180 (48.6)
Proximal and distal lesions, n (%) 66 (8.7) 14 (25.5) 25 (13.3) 0 (0.0)
Vascular laboratory assessment
Pain-free walking distance, median
(IQR), m
80.0 (40.0–130.0) 70.0 (40.0–130.0) 80.0 (50.0–140.0) 70.0 (30.0–130.0) 0.69
Maximum walking distance,
median (IQR), m
250.0 (140.0–500.0) 230 (120.0–400.0) 250.0 (140.0–520.0) 280.0 (160.0–500.0) 0.028
Resting ankle-brachial index,
median % (IQR)




35.0 (26.0–54.0) 28.0 (20.0–39.0) 32.0 (25.0–46.0) 41.0 (30.0–62.0) <0.001
Overall P values for each comparison are provided. IQR indicates interquartile range; PAD, peripheral arterial disease.
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Discussion
This study in patients with new diagnosis of PAD (Rutherford
grade I; patients with mild, moderate, and severe claudica-
tion) provides further insight into strategies that can poten-
tially help risk-stratify these patients based on a simple
comparison by the number of lower extremity arterial lesions
identified at presentation. In addition, this study is the first, of
which we are aware, to estimate PAD patient risks of
experiencing multiple adverse events over time, using novel
multiple-event modeling techniques. In a vascular specialty
setting, we found that half of our patients presented with 1
lesion, whereas a quarter had ≥3 lesions on diagnosis. At
least 1 adverse event was observed in a quarter of the
population, and only a minority (5%) experienced ≥2 events
during the 3-year study follow-up. Having more lower
extremity lesions (≥3) was not only predictive of an increased
risk of experiencing a first adverse event, as assessed by a
traditional time-to-first-event Cox regression model, but also
was associated with experiencing multiple events over
time compared with patients having an isolated lesion, as
modeled with a Cox-based intensity-elapsed time model. In
addition, the results remained consistent throughout our
analyses despite adjusting for known traditional PAD risk
factors.
Figure 1. The cumulative incidence of a first adverse event by
number of lesions during median follow-up of 3.2 years. The
comparison of ≥3 lesions vs 0 to 1 lesion (reference category) was
statistically significant at the P<0.001 level.
Table 2. Total Number of Patients and Events by Event





















5/8 2/3 1/2 2/3
Unstable angina,
%
34/36 8/8 9/11 17/17
Myocardial
infarction, %
33/37 14/14 4/5 15/18
Heart failure, % 22/28 6/10 7/7 9/11
Cerebrovascular
accident, %
22/23 7/7 7/7 8/9
Death, % 87/87 33/33 18/18 36/36
Table 3. The Association Between the Number of Lesions
and 3.2-Year First Adverse Event Risk
Hazard
Ratio 95% CI P Value
Number of lesions
2 vs 1 0.85 0.55–1.31 0.46




Age (per +10 years) 1.32* 1.08–1.62 0.006
Female 1.05 0.73.1.50 0.81
Body mass index 1.01 0.97–1.04 0.79
Prior angina 1.49 0.95–2.33 0.08
Prior myocardial infarction 1.52 1.00–2.31 0.05







Prior stroke 1.20 0.66–2.20 0.55




Hypertension 1.16 0.79–1.68 0.45
Dyslipidemia 1.21 0.83–1.75 0.32
Diabetes mellitus 1.11 0.75–1.63 0.61
Renal dysfunction 1.03 0.62–1.71 0.91
Smoking 1.35 0.94–1.94 0.11




Systolic blood pressure, mm Hg 1.00 0.99–1.01 0.78
Proximal lesion 0.98 0.68–1.42 0.93
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Although it seems obvious to assume that patients
with multiple lower extremity arterial lesions have poorer
prognosis compared with those having a single lesion, prior
studies demonstrated only that PAD patients with concomi-
tant coronary or carotid disease (ie, having several arterial
beds affected) have increased risks of experiencing adverse
events compared with those having a single arterial bed
affected.3,5,16 These studies were unable to perform compar-
isons based on the number of lesions within 1 arterial bed
(lower extremity arteries) for patients with PAD.3,5,16 Only 1
small study of 224 younger nondiabetic patients recruited in
1985 demonstrated that patients with multiple lower extrem-
ity arterial lesions had lower 6-year survival rates compared
with patients having a single lesion.9 Because of its many
limitations, including a nondiabetic population that is not
necessarily representative of the PAD population, lack of
visualization of arterial segments, and limited sample size, this
older study did not draw any firm conclusions about the
prognostic association of the number of lesions in lower
extremity PAD with outcomes. Other research supporting our
findings comes from the BASIL trial data, in which the number
of ankle-pressure measurements that could be detected
(dorsalis pedis, posterior tibial, and perforating peroneal;
range 0–3) was included in a prediction model to predict 2-
year survival in critical limb ischemia patients—a more
advanced expression of PAD. The number of detectable ankle-
pressure measurements was associated with 2-year survival
in a dose-response–related way in which the highest survival
rates were noted among patients with 3 pressures and the
lowest survival rates were seen among patients without
Figure 2. The association between number of lesions and first adverse event risk, stratified by event type.
The hazard ratios and 95% CIs are depicted for lower extremity amputation, unstable angina, myocardial
infarction, heart failure, stroke, and mortality. The reference group for the comparisons was the group of
patients having nonsignificant lesions or 1 significant lesion (0–1 lesion). Overall P values for each
comparison are provided. CVA indicates cerebrovascular accident.
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detectible pressures.10 In the current study, we had a unique
chance to examine the association between arterial lesions
and prognosis in a larger cohort of patients with earlier stages
of PAD in which adverse risk factors were proportionally
represented in accordance with their prevalence in a real-
world clinical setting.3,5 Lesions were documented with
modern duplex ultrasound techniques on diagnosis. Detailed
and complete follow-up information was available for first and
multiple events. Our study maximized the use of information
on multiple events into state-of-the-art analytic models and
has the potential to significantly advance our understanding of
different subpopulations of patients with PAD.
Our results suggest that the risk of adverse events may
increase along with the number of lower extremity lesions.
This raises the question whether it is possible that the
manifestation of atherosclerosis may present differentially
among individual patients’ arteries. More aggressive expres-
sion of atherosclerosis has been found in patients with distal
versus aortoiliac disease and in patients in whom higher
inflammation markers can be found.17–19 These studies
suggested which concomitant factors could be associated
with a more aggressive underlying atherosclerotic process but
were unable to document whether this could be linked to the
number of lower extremity lesions and patient outcomes.17,18
Consequently, future work needs to verify whether having
more lower extremity lesions is associated with a more
aggressive underlying atherosclerotic process expressed by
higher inflammation markers or undergoing multiple lower
extremity revascularizations to better characterize PAD sub-
populations that are at increased risk of an adverse prognosis.
Apart from investigating the potential pathophysiological
underpinnings for the adverse prognosis associated with
having more arterial lesions, our results indicate that infor-
mation on the number of lesions—as derived from various
radiological imaging instruments—adds to the prognostic
information derived from traditional PAD risk factors that we
adjusted for in our models. It may also offer some predictive
information beyond the established risk stratification based
on patient ABI20; we found in our preliminary analyses that the
number of lesions remained predictive of patient prognosis
after adjusting for ABI. Nevertheless, further validation work in
this area is needed. Future studies need to evaluate whether
implementing quality-of-care protocols specifically directed at
the subgroups of patients presenting with multiple lesions (eg,
closer patient monitoring in combination with aggressive
adverse risk management and more proactive screening for
coronary or cerebrovascular disease) may be able to curb the
adverse risk observed in patients with PAD presenting with
multiple lesions. Assessing patients’ true cumulative risk of
having multiple adverse events over time is becoming more
standard within cardiovascular research21,22 but rarely has
been applied for research investigating PAD populations.
Future efforts should focus on ways in which we can more
accurately predict patients’ overall risk of experiencing
multiple future events following a diagnosis of PAD, using
state-of-the-art analyses.15 Although we did not observe a
great number of multiple adverse events during the limited 3-
year study follow-up, these techniques seem even more
relevant when investigating longer term outcomes and the
need for recurrent procedures in this vulnerable patient group.
Figure 3. The cumulative incidence of experiencing multiple
adverse events in patients stratified by event type (lower extremity
amputation, unstable angina, myocardial infarction, heart failure,
stroke, and mortality) during median follow-up of 3.2 years. CVA
indicates cerebrovascular accident.
Figure 4. The association between the number of lesions and
cumulative incidence of major adverse cardiac events (MACE)
during median follow-up of 3.2 years. Multiple MACE occurring at
any time in patients are taken into account. The reference group for
the comparisons was the group of patients having nonsignificant
lesions or 1 significant lesion (0 to 1 lesion). The overall P value for
the comparisons was P<0.009.
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Our results should be interpreted in the context of the
following potential limitations. Not all arterial segments were
visualized because duplex ultrasound testing was guided by
the vascular surgeon’s clinical evaluation, including history
taking, ABI assessment, and physical examination, thereby
checking the presence of arterial pulses; however, chances
that lesions were missed are minimal because duplex
ultrasound testing was performed using a systematic
approach (ie, segments were additionally visualized if a lesion
was expected elsewhere due to flow disturbances). Informa-
tion on individual lesion complexity or length of the stenosis
was not accounted for in our analyses, and future research
remains to be done on whether this granular anatomical
lesion information may further improve the risk stratification
of patients with PAD. Although duplex ultrasonography has
been shown to have a median sensitivity of 88% and a
specificity of 96% to detect a stenosis of ≥50% or an occlusion
when imaging the whole leg versus the standard of contrast
angiography, we acknowledge the potential for misclassifica-
tion of arterial lesions.14 To maximize our power, we explored
patient risk of adverse events by use of a composite end
point, but we also explored patient risk by event type, using a
multivariate analysis, and further ran sensitivity analyses by
restricting our end point to fatal or nonfatal MI or stroke; for
all of these analyses, the association between the number of
arterial lesions and adverse prognosis persisted. In addition,
because patients were recruited from 2 vascular surgery
outpatient clinics and patients with critical limb ischemia were
excluded, our results may not necessarily be generalizable to
the whole spectrum of PAD patients and to patients with PAD
seen in other settings. Future formal validation work is
needed in similar, larger cohorts to establish firm clinical
management guidelines based on the discriminatory ability of
the number of lesions to better risk-stratify patients with PAD.
Furthermore, we did not adjust for treatments that patients
received after their baseline visit. Finally, although we
adjusted for clinically important factors, we cannot rule out
the possibility of residual confounding due to the observa-
tional nature of our study.
Conclusions
This study demonstrated that PAD patients presenting with
more lower extremity arterial lesions on diagnosis were at
increased risk of experiencing a first and multiple adverse
events over time compared with those having only 1 lesion.
Comparing PAD outcomes as a function of patients’ number
of lower extremity lesions may offer a new paradigm that may
serve clinicians to better determine patient risk for an adverse
prognosis at initial PAD diagnosis. Our findings also may open
up new possibilities to develop and evaluate care innovations
directed specifically at patients who present with ≥3 lesions
within their lower extremity arteries, possibly representing a
phenotype that is associated with a more aggressive form of
atherosclerotic disease.
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SUPPLEMENTAL MATERIAL 
FIGURE S1 – Flow Chart of the Study Population 
 
 
FIGURE S2 – The Mean Cumulative Incidence for Experiencing Multiple Adverse Events 
by the Number of Lesions during a Median Follow-Up of 3.2-Years. The estimated cumulative 
incidence curves for 0-1 and 2 lesions were virtually identical, and therefore they are labeled as 




TABLE S1 - The Association between the Number of Lesions and 3.2-Year Multiple 







Number of lesions    
2 vs. 1 0.92 0.64-1.34 .67 
3+ vs. 1 1.53 1.08-2.18 .018 
Resting ankle-brachial index (per +10%) 0.92 0.84-1.01 .07 
Age (per +10 years) 1.30 1.10-1.54 .003 
Female 1.04 0.77-1.39 .82 
Body mass index (per +5 kg/m2) 1.08 0.93-1.26 .32 
Prior angina 1.15 0.79-1.68 .46 
Prior myocardial infarction 1.47 1.04-2.09 .031 
Heart failure 1.76 1.05-2.95 .033 
Prior coronary artery bypass graft 1.11 0.74-1.67 .60 
Prior percutaneous coronary intervention 1.32 0.86-2.03 .20 
Prior stroke 1.25 0.74-2.09 .40 
Prior transient ischemic attack 0.58 0.34-1.00 .05 
Chronic obstructive pulmonary disease 1.80 1.30-2.51 <.001 
Hypertension 1.07 0.78-1.49 .67 
Dyslipidemia 1.24 0.89-1.72 .20 







Table S1 (continued)    
Renal dysfunction 1.09 0.70-1.67 .71 
Smoking 1.45 1.06-1.98 .020 
Total cholesterol (per +50 mg/dL) 0.88 0.73-1.07 .19 
High-density lipoprotein cholesterol (per +10 mg/dL) 1.08 0.97-1.21 .16 
Systolic blood pressure (per +10 mmHg) 1.01 0.95-1.08 .72 
Proximal lesion 0.79 0.58-1.10 .16 
Abbreviations: kg=kilogram, m2=square meters, mg/dL=milligrams per deciliter, 
mmHg=millimeters of mercury. 
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